You are here

Portable hand-held non-mydriatic retinal camera

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43EY021974-01A1
Agency Tracking Number: R43EY021974
Amount: $189,133.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NEI
Solicitation Number: PA12-088
Timeline
Solicitation Year: 2013
Award Year: 2013
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
2501 Yale Blvd. SE
ALBUQUERQUE, NM -
United States
DUNS: 804567217
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 PETER SOLIZ
 (505) 508-1994
 psoliz@visionquest-bio.com
Business Contact
 PETER SOLIX
Phone: (505) 508-1994
Email: psoliz@visionquest-bio.com
Research Institution
 Stub
Abstract

DESCRIPTION (provided by applicant): According to the National Institutes of Health, there are more than 80 million people in the US who suffer from a potentially sight-threatening disease. Doctors see seven to eight million new cases of eye disease annually. More than two million Americans age 50 and older have advanced AMD, the stage that can lead to severe vision impairment and 10 million have early or intermediate AMD. Glaucoma affects more than 2.3 million Americans age 40 and older. Another two million individuals with glaucoma are undiagnosed. Diabetes cases in the US and throughout the world have been on the rise. Poor eating habits and lack of exercise, factors which contribute to type 2 diabetes, have led to an increasingly overweight population. According to the International Diabetes Federation, there are 285 million cases of diabetes in the world as of 2010. For the type 2 diabetics, 50% will develop diabetic retinopathy within 15 years of disease diagnosis. Regular eye disease screening is necessary to prevent the progression of eye diseases to advanced, sight-threatening stages. The objective of this project is to develop and test a low-cost, hand-held, non-mydriatic retinal camera for widespread applications, including teleretinal screening foreye diseases such as diabetic retinopathy, glaucoma, and age-related ocular diseases. The proposed camera fills an important unmet need: low-cost (under 1,500 cost of goods); small footprint (principally a hand-held device); and easy to use (ergonomically designed for operation by a minimally trained medical technician or nurse). Introducing this technology to a clinic environment will allow underserved individuals to receive regular eye screenings without traveling to an eye care professional. To meet this goal, our proposal has two aims. First, we will produce a prototype of the low-cost, hand-held, non-mydriatic camera, which will be based on an early prototype of a mydriatic camera that was developed, and for which early testing has shown significantfunctionality. The design is based on low-cost, off-the-shelf components that can be assembled easily for a high- volume market. Second, we will test this camera in a screening or clinic environment. Making the camera ergonomically suitable for use by a minimally trained individual will be the goal of this aim. Quantitative analysis will be performed as to field of view, resolution, and safety. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Retinal screening for diseases such as diabetic retinopathy is performed currently with specialized cameras that cost approximately 20,000. For small medical practices and clinics, especially those in underserved areas who are most in need of screening technology, this cost is prohibitive. In this project, we will develop a non-mydriatic, low-cost, hand-held camera that could be sold for 5,000 as a component of a telemedicine-based eye disease screening system.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government